Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
Observational · No treatment assigned · Sites not listed yet · Assiut University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Inclusion Criteria: 1) Age ≥ 18 years; 2) Patients with moderate-to-severe ulcerative colitis, defined as a clinical Mayo score >6 with an endoscopic score of 2-3 3) Patients with moderate-to-severe Crohn's disease, defined as a Crohn's…
- Exclusion Criteria:
- Patients with prior biologic therapy (biologic-experienced);
Plus 4 more requirement(s). Only the trial team can confirm whether you qualify.
What's involved
- About 95 participants are expected to take part.
- Start date: 2026-03-01 (planned).
- Main results expected around 2027-03 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- Efficacy of different biological treatment on patient with inflammatory bowel disease after one year of treatment in upper egypt (1 year)
In the researchers’ words
To study the efficacy of different biological treatment on patient with inflammatory bowel disease after one year of treatment in upper egypt
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) |
| Lead sponsor | Assiut University |
| Enrollment | 95 (estimated) |
| Start date | 2026-03-01 |
| Primary completion (est.) | 2027-03 |
| First posted | 2026-03-27 |
| Last updated | 2026-03-27 |
| Official title | Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt |
| ClinicalTrials.gov ID | NCT07495644 |
Interventions
- adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab (Biological)
Efficacy of different biological treatment on patient with inflammatory bowel disease
Full eligibility criteria (from the record)
1. Inclusion Criteria: 1) Age ≥ 18 years; 2) Patients with moderate-to-severe ulcerative colitis, defined as a clinical Mayo score >6 with an endoscopic score of 2-3 3) Patients with moderate-to-severe Crohn's disease, defined as a Crohn's Disease Activity Index (CDAI) >220 with a Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥7 4) Patients receiving adalimumab, infliximab, ustekinumab, or vedolizumab; 5) Patients who had been on the current biologic therapy for between 6 weeks and 12 months; and 6) Biologic-naïve patients (no prior biologic therapy). Patients who did not continue their treatment for 12 months due to primary or secondary treatment failure will be considered not to have achieved endoscopic remission. Additionally, patients who were hospitalized, received corticosteroids, or underwent surgery due to medication failure before 12 months of therapy will be considered treatment failures. 2. Exclusion Criteria: 1. Patients with prior biologic therapy (biologic-experienced); 2. Patients with incomplete outcome or therapy data; 3. Patients receiving other concomitant biologic or small-molecule therapies for other conditions, such as rheumatological diseases; 4. Pregnant patients; 5. Patients with intermittent suspension of therapy during the 12-month period.
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.